OATP2B1 as a modifier of abiraterone activity in cancer cells was further investigated in a clinical trial, where the genetic variants of SLCO2B1 namely the coding rs12422149 (c.935G>A) and the intronic rs1789693 correlated with tissue concentrations of abiraterone. This evidence concerns the gene SLCO2B1 and cancer.